Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018

Business Wire April 25, 2018

Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018

Business Wire April 24, 2018

Revance Investor Day Highlights New Neuroscience Indications in Development

Business Wire April 19, 2018

Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable

Business Wire April 2, 2018

Revance to Host Investor Day on April 19, 2018

Business Wire March 26, 2018

Revance to Participate in the Needham Healthcare Conference

Business Wire March 20, 2018

Revance to Participate in Upcoming Investor Conferences

Business Wire March 6, 2018

Revance Releases Fourth Quarter and Full Year 2017 Results

Business Wire February 28, 2018

Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics

PR Newswire February 28, 2018

Revance Therapeutics, Inc. to Host Earnings Call

Accesswire February 28, 2018

Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018

Business Wire February 22, 2018

Revance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference

Business Wire February 14, 2018

Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018

Business Wire February 1, 2018

Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis

Business Wire January 8, 2018

Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018

Business Wire January 4, 2018

Report: Exploring Fundamental Drivers Behind Blackhawk Network, TrueCar, Home BancShares, Revance Therapeutics, Heritage Financial, and GMS — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire January 3, 2018

Revance Announces Closing of Public Offering of Common Stock

Business Wire December 11, 2017

Revance Announces Pricing of Public Offering of Common Stock

Business Wire December 7, 2017

Revance Announces Proposed Public Offering of Common Stock

Business Wire December 5, 2017

Mid-Afternoon Market Update: Francesca's Drops On Earnings Miss; Revance Therapeutics Shares Gain

Benzinga.com  December 5, 2017